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Abstract
Background: Russia is a high tuberculosis (TB) burden country with a high prevalence of
multidrug resistant tuberculosis (MDRTB). Molecular assays for detection of MDRTB on clinical
specimens are not widely available in Russia.
Results: We performed an evaluation of the GenoType® MTBDRplus assay (HAIN Lifescience
GmbH, Germany) on a total of 168 sputum specimens from individual patients at a public health
laboratory in Central Russia, as a model of a middle income site in a region with high levels of drug
resistance. Phenotypic drug resistance tests (DST) were performed on cultures derived from the
same sputum specimens using the BACTEC 960 liquid media system.
Interpretable GenoType® MTBDRplus results were obtained for 154(91.7%) specimens with
readability rates significantly higher in sputum specimens graded 2+ and 3+ compared to 1+ (RR =
1.17 95%CI 1.04–1.32). The sensitivity and specificity of the assay for the detection of rifampicin
(RIF) and isoniazid (INH) resistance and MDR was 96.2%, 97.4%, 97.1% and 90.7%, 83.3%, 88.9%
respectively. Mutations in codon 531 of the rpoB gene and codon 315 of the katG gene dominated
in RIF and INH resistant strains respectively. Disagreements between phenotypical and molecular
tests results (12 samples) could be explained by the presence of rare mutations in strains circulating
in Russia and simultaneous presence of resistant and sensitive bacilli in sputum specimens
(heteroresistance).
Conclusion: High sensitivity, short turnaround times and the potential for screening large
numbers of specimens rapidly, make the GenoType® MTBDRplus assay suitable as a first-line
screening assay for drug resistant TB.
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Emergence of multidrug resistance tuberculosis (MDRTB,
i.e. resistance to at least rifampicin (RIF) and isoniazid
(INH) in conjunction with increasing rates of HIV infec-
tion worldwide makes the rapid detection of TB drug
resistance a key factor in patients' management and care.
Rapid (within 1–2 days) diagnosis of MDRTB in clinical
specimens allows the commencement of an appropriate
TB treatment regimen earlier and helps to prevent trans-
mission of drug resistant TB bacilli.
The WHO estimates current MDRTB rates in new and pre-
viously treated cases globally at 2.9% and 15.3% respec-
tively, with 57% of MDRTB cases coming from three high
burden countries (China, India, and the Russian Federa-
tion) [1]. MDRTB is more expensive to treat and survival
rates (especially in HIV-infected persons) are much lower
compared to drug-sensitive TB, which poses a particular
problem for low- and middle-income countries like Rus-
sia where HIV and TB epidemics are converging and access
to second- and third line drug therapy is limited [2,3].
More than 90% of M. tuberculosis (MTB) strains phenotyp-
ically resistant to RIF and INH respectively harbour point
mutations in a 81 bp "core" region of rpoB gene (RIF),
codon 315 of the katG gene and/or regulatory region of
the inhA gene (INH); other molecular mechanisms of INH
resistance include mutations in ahpC-oxyR intergenic
region and other regions of inhA and katG genes [4-7].
Various molecular techniques, including conventional
sequencing, pyrosequencing, real-time PCR and reverse
hybridization assays with DNA probes have been pro-
posed recently for detection of mutations associated with
drug resistance with the latter methodology successfully
realised in a number of in-house and commercial assays
[8-11].
Increasing TB and MDRTB rates, particularly in high TB
burden countries, require development and implementa-
tion of rapid diagnostic systems able to detect MTB and
MDRTB in clinical specimens [12,13]. Automated liquid
culture systems have significantly shortened turnaround
times compared to solid media, but still require isolation
of mycobacterial cultures prior to drug resistance testing;
implementation of these systems may not be feasible in
laboratories in low- to middle income countries with a
high TB and drug resistance burden due to infrastructure
limitations, lack of resources and appropriately trained
personnel [14].
A limited number of commercial assays for testing clinical
specimens (sputum) is currently available on the market,
including INNO-LiPA Rif.TB (Innogenetics N.V, Ghent,
Belgium) and GenoType® MTBDR (HAIN Lifesciences
GmbH, Nehren, Germany) [15-17]. The new version of
the latter assay (GenoType® MTBDRplus), targeting the
rpoB gene associated with the resistance to RIF and both
genes (katG and inhA) associated with the resistance to
INH has been evaluated mainly on cultures and clinical
specimens in various low incidence settings, demonstrat-
ing excellent specificity and good concordance with phe-
notypical DST results [11,18,19]. A recent study
demonstrated the feasibility of this assay as a screening
tool when applied in a high-volume public health labora-
tory in a high TB and HIV, but low drug resistance, inci-
dence area [19].
Russia is a high TB burden country with high rates of TB
drug resistance and dominance of Beijing strains reported
to be associated with MDRTB [1,20,21]. The current offi-
cial regulations for TB laboratory diagnosis in Russia do
not recommend molecular tools for drug susceptibility
testing on cultures and clinical specimens. The Samara
oblast (Central Russia) is a hot spot of both TB and HIV
epidemics with rates of MDR in new TB cases of approxi-
mately 20% rising even higher in previously treated cases
and the prison sector [20].
We performed an analysis of the performance of the Gen-
oType® MTBDRplus assay (HAIN Lifesciences GmbH,
Nehren, Germany) at the Samara Regional TB Reference
laboratory, which is a busy public health laboratory serv-
ing a population of 3,000,000 people in the Central Rus-
sia, as a model of a middle income site in a region with
proven high levels of anti-TB drug resistance. Data from
this study contributed to the development of WHO policy
on the utility of these assays for MDRTB scsreening.
Methods
Clinical specimens, microscopy, identification and 
phenotypic drug susceptibility tests
A total of 168 consecutive patients provided smear-posi-
tive sputum samples (79 samples from new cases and 89
from previously treated patients) at two participating
sites: Samara Oblast TB Dispensary and Samara Oblast TB
Hospital. Baseline demographic data, including date of
birth, gender, residence address, and evidence of previous
anti-TB treatment was compiled from patients' medical
records and entered into an Access database. The study
was approved by the Samara Medical University Ethics
Committee. The study was conducted in accordance with
the STARD principles for diagnostic accuracy studies: all
staff were trained in culture and molecular techniques by
the authors and product manufacturer, achieved an
appropriate level of proficiency and those performing the
molecular analyses were blinded to the reference method
of culture-based DST using the MGIT 960 and clinical
data.
Sputum specimens (1 specimen per patient) were proc-
essed using NALC-NaOH decontamination method
(NaOH final concentration 1%) as described elsewherePage 2 of 9
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sediment was resuspended in 1.0 – 1.5 ml of phosphate
buffer and used for smear preparation (Ziel-Nielsen stain-
ing), culturing and DNA extraction. Smear grading was
performed using WHO recommendations [23].
Mycobacteria were cultured using BACTEC MGIT960 liq-
uid culture systems (Becton Dickinson, Cockeysville,
USA) and conventional Lowenstein-Jensen media and
identified by molecular assays (GenoType Mycobacterium
CM, HAIN Lifesciences GmbH, Nehren, Germany)
according to manufacturer's guidelines. Phenotypic drug
susceptibility tests (DST) for resistance to RIF and INH
were performed using the BACTEC MGIT960 according to
the manufacturer's recommendations and as described
elsewhere [24-26]. Where results of Mycobacteria culturing
and/or DST using the liquid culture system were uninter-
pretable, isolates (N = 4) were inoculated and subse-
quently tested for drug resistance using the absolute
concentration method on solid (Lowenstein-Jensen)
media.
Detection of mutations associated with drug resistance
Identification of mutations in rpoB, katG, and inhA genes
associated with resistance to RIF and INH in all sputum
specimens and a proportion (N = 78) of Mycobacterial cul-
tures was performed using GenoType® MTBDRplus kits
(HAIN Lifesciences GmbH, Nehren, Germany) according
to the manufacturer's recommendations. Briefly, crude
DNA was extracted from sputum specimens and cultures
by heating suspensions in a dry heating block followed by
an incubation on ultrasonic bath. PCR (50 μl/tube) was
performed using HotStar Taq DNA Polymerase (Qiagen,
Crawley, UK). The number of PCR cycles was 30 and 40
for DNA samples extracted from cultures and sputum,
respectively. Prior to hybridization, PCR products were
analysed in 1.5% agarose gel stained with ethidium bro-
mide.
After hybridization, membrane strips were attached to the
evaluation sheet, read and interpreted by an operator
(who was blinded to the bacteriological results and vice
versa) according to the manufacturer's recommendations.
All laboratory work (microscopy, bacteriological identifi-
cation, DST and molecular testing) was performed at lab-
oratories of Samara Oblast TB service (Samara, Russian
Federation).
Results
Smear microscopy, bacteriological identification and 
phenotypic drug susceptibility tests
All sputum samples were graded depending on AFB count
in the specimen according to the WHO recommendations
[23] with 64 samples (38.1%) graded 1+; 60 samples
(35.7%) 2+; 42 (25.0%) 3+; two samples contained less
than 10 AFB in 100 fields (Table 1). Seventy-nine sputum
specimens (47.0%) were collected from patients who had
not been treated for TB, and remaining samples were from
previously treated patients.
Mycobacterial cultures were isolated from all sputum
specimens included in the study. Vast majority of isolates
(165, i.e. 98.2%) were identified as M. tuberculosis com-
plex using the molecular (GenoType Mycobacterium CM)
tests, and three more isolates were correctly identified as
M. kansasii.
Valid phenotypic DST results were obtained for 161 cul-
tures (157 on liquid media and 4 on solid LJ media; DST
tests were not performed on M. kansasii isolates). No phe-
notypic DST results were obtained for four M. tuberculosis
complex cultures heavily contaminated with fast growing
bacterial and/or fungal flora. The number of strains resist-
ant to RIF, INH, and MDR in the test collection was 111,
118, and 110 comprising 69.0%, 73.3%, and 67.7%
respectively.




Unreadable GenoType® MTBDRplus patterns
(N = 14)
Unusual (double) GenoType® MTBDRplus pat-
terns
(N = 39)
1 – 9 AFB/100 fields (n = 2) 1 (50.0%) 0
1+ (n = 64) 11 (17.2%) 21 (32.8%)
2+ (n = 60) 2 (3.3%) 12 (20.0%)
3+ (n = 42) 0 6 (14.3%)
New cases (N = 79) 7 (8.9%) 17 (21.5%)
Previously treated cases (N = 89) 7 (7.9%) 22 (24.7%)Page 3 of 9
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resistance using GenoType® MTBDRplus assay on sputum 
specimens
Readable GenoType® MTBDRplus assay results were
obtained for 154 DNA extracts obtained from sputum
samples comprising 91.7% of all extracts available for
testing. Of these three strips had no TB bands indicating
the presence of non-TB Mycobacteria (later cultures grown
from these specimens were identified as M. kansasii using
the HAIN CM assay). GenoType® MTBDRplus strips for
the remaining 14 samples were unreadable having either
no bands at all or very weak/unreadable bands in rpoB,
katG and/or inhA sections.
Analysis of test results demonstrated that ability to read
and interpret GenoType® MTBDRplus assay results varied
depending on the concentration of Mycobacteria in spu-
tum samples (Table 1). Generally, better results (96.7%–
100.0% readable results) were achieved with sputum sam-
ples with higher AFB counts (2+...3+), whilst for samples
containing less Mycobacteria (1+) the performance of the
assay was poorer (50.0% – 82.8%). Molecular assay read-
ability rates were significantly higher in specimens graded
2+ than in specimens graded 1+ (RR = 1.17 95% CI 1.04
– 1.32). There were no differences in sensitivity of the
assay between sputum samples collected from new
patients and those previously treated for TB.
Mutations conferring resistance to RIF and INH were
detected in 107 and 117 DNA samples extracted from spu-
tum, respectively; all DNA samples where RIF resistance
was detected also had mutations in katG and/or inhA
genes indicating they were INH resistant, i.e. MDR (Tables
2, 3). In a vast majority of RIF-resistant isolates (N = 101;
94.4%) codon 531 was affected (including five strains
where mutations in the codon 531 were combined with
mutations in other codons). Mutations in other codons of
rpoB gene were less common affecting a total of 11 strains
(10.3% of all RIF-resistant strains). Mutations associated
with INH resistance were more diverse: eighty strains
(68.4%) had mutations in katG (codon 315) gene only,
four strains (3.4%) had mutations in the inhA gene only
(position (-15) in the mabA-inhA promoter), and remain-
ing strains had mutations both in katG and inhA genes
(Table 2). No mutations in the position (-8) of the mabA-
inhA promoter were identified.
Although most specimens produced results with either
wild type OR mutant probes being positive on the hybrid-
ization strip, in a proportion of specimens (N = 39, 25.3%
of all readable GenoType® MTBDRplus results) both
mutant and wild types probes were visible ("double pat-
terns"), in katG and inhA genes only (Tables 1 and 3).
According to manufacturer's recommendations these
results may be indicative of either the presence of heterog-
enous strains or mixed populations of Mycobacteria in ini-
tial sputum specimens and were all interpreted as resistant
to the relevant drug.
Double patterns were more common in DNA specimens
extracted from sputa with lower concentration of AFB
bacilli (Table 1); prevalence of double patterns was signif-
icantly higher in specimens graded 1+ compared to speci-
mens graded 2+ and 3+ (18/102 vs 21/64 RR = 1.8 95%
CI 1.04 – 3.12).
Comparative analysis performed on 149 pairs of DST
results (phenotypical DST failed for two specimens for
which molecular data was available) demonstrated good
overall agreement between molecular (sputum speci-
mens) and phenotypic DST results with molecular and
phenotypic tests being identical (resistant or sensitive) in
141 (94.6%) and 140 (94.0%) specimens for RIF and INH
susceptibility respectively (Table 3). Sensitivity and posi-
tive predictive values were generally higher
(95.3%...97.4%) for detection of resistant strains whereas
specificity and negative predictive values were higher
(96.6%...97.4%) for detection of sensitive strains indicat-
ing that the molecular assay tends to overestimate resist-
ance when applied on direct sputum specimens.
The total number of discrepant results was 17 (8 disagree-
ments for rifampicin resistance and 9 disagreements for
isoniazid resistance in a total of 12 strains) (Table 4). In
seven cases (comprising respectively 3.8% and 2.7% of all
RIF and INH phenotypically resistant isolates) "wild" type
hybridization patterns in relevant genes were registered in
DNA samples extracted from sputum specimens which
then produced resistant M. tuberculosis cultures probably
indicating the presence of less common mutations not
detected by the current version of the MTBDRPlus assay.
"Mutant" rpoB gene patterns and "mutant" katG and/or
inhA patterns were registered respectively in four (9.3%)
and six (16.7%) DNA samples, from which phenotypi-
cally sensitive M. tuberculosis strains were then derived.
There were no associations between specific types of
mutations (or GenoType® MTBDRplus patterns) and disa-
greements between molecular and phenotypic results
(Table 4).
Detection of mutations associated with drug resistance 
using GenoType® MTBDRplus assay on culture specimens
To validate results of the GenoType® MTBDRplus assay on
sputum samples and address issues related to "double pat-
terns" and discrepancies between molecular (sputum)
and phenotypic results, we tested a panel (N = 78) of cul-
tures for RIF and INH resistance using GenoType® MTB-
DRplus assay (Tables 1 and 4). This panel included 38 of
39 cultures derived from sputum specimens that had pro-Page 4 of 9
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Table 2: Variety of mutations associated with RIF and INH resistance (sputum specimens)
Drug resistance patterns No of strains resistant to relevant drug %
RIF resistance pattern (rpoB gene)
WT probes Mutant probes N = 107
Δ8 S531L 93 86.9
Δ8 - 3 2.8
Δ7 H526Y 1 0.9
Δ7 H526D 1 0.9
Δ7,Δ8 - 3 2.8
Δ6 - 2 1.9
Δ3,Δ8 D516V, S531L 1 0.9
Δ3,Δ8 D516V 1 0.9
Δ2,Δ7 - 1 0.9
Δ2,Δ4 - 1 0.9
INH resistance pattern
katG inhA
WT probes Mutant probes WT1 probe WT2 probe Mutant probes N = 117
Δwt S315T1 WT WT - 68 58.1
Δwt S315T1 WT WT C15T 5 4.3
Δwt S315T1 WT Δwt - 2 1.7
Δwt S315T1 Δwt WT C15T 2 1.7
Δwt S315T1 Δwt WT - 2 1.7
Δwt S315T1, S315T2 WT WT - 1 0.9
WT - Δwt WT C15T 3 2.6
WT - WT WT C15T 1 0.9
WT S315T1 WT WT - 11 9.4
WT S315T1 WT WT C15T 16 13.7
WT S315T1 WT WT A16G 1 0.9(page number not for citation purposes)
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greements as well as a 30 other randomly selected
samples. Readable molecular results were obtained for all
specimens.
Comparison of results revealed some disagreements
between three sets of data (molecular DST on sputum,
molecular DST on culture, phenotypical DST). In a group
of isolates phenotypically sensitive to RIF derived from
sputum samples identified as resistant using the Geno-
Type® MTBDRplus assay (N = 4), no mutations in rpoB
gene were found. Similarly, there were no mutations in
katG and inhA genes in four of six phenotypically sensitive
to INH isolates derived from "resistant" sputum speci-
mens (one isolate was not tested and one more had muta-
tion in the katG gene). The prevalence of "double"
hybridization patterns in DNA specimens extracted from
cultures was substantially lower compared to those
extracted from sputum (25.8% vs 6.4%, RR 4.03 95%CI
1.65 – 9.81). There were no discrepancies in mutations
detected in DNA specimens extracted from sputum speci-
mens and cultures derived from these specimens (Table
4).
Discussion
In the current study we evaluated the performance of the
molecular assay (HAIN Lifescience GmbH GenoType®
MTBDRplus) for rapid detection of resistance to the most
important anti-TB drugs (RIF and INH) on sputum sam-
ples in the region with middle TB incidence and high
prevalence of MDRTB in Russian Federation (Samara
oblast). Until now, within the Russian Federation, there
was only limited evidence of applicability of rapid molec-
ular techniques (biochips) for detection of mutations
conferring drug resistance directly in clinical specimens
[27]; molecular assays for diagnosis of anti-TB drug resist-
ance are not widely available in the Russian Federation, a
high TB burden country [1].
Substantial reduction in the time to diagnose drug-resist-
ant TB, the earlier commencement of appropriate therapy
and the potential to prevent transmission of drug-resistant
strains constitutes the major advantages of these methods.
Recent studies demonstrated the feasibility of the MDRT-
BPlus assay as an effective tool for MDRTB screening in a
high TB, and high MDRTB incidence, region and good
concordance with phenotypic DST results [11,18,19].
However, rapid DST on clinical samples using molecular
tools has (or potentially may have) a number of draw-
backs, generally related to the low concentration of bacilli
and possible presence of various types of Mycobacteria (eg
sensitive and resistant ones) in the sputum specimen. The
former issue, potentially leading to a problems with an
assay sensitivity, has been addressed by incorporation of
two stages (nested) PCR or increasing of number of PCR
cycles (INNO-LiPA Rif.TB and GenoType® MTBDRplus
respectively), but the sensitivity was still low in smear-
negative culture-positive samples [11,18,28]. In addition,
increase in assay sensitivity achieved by a large number of
PCR cycles may lead to increased sensitivity to bacterial
and/or amplicon contamination. The sensitivity of the
assay may also be affected by a suboptimal selection of
DNA probes and targets for the population studies
because prevalence of mutations associated with RIF and
INH resistance vary in different geographical regions
[5,29,30].
In our collection of strains the spectrum of mutations
associated with the resistance to RIF and INH (dominance
of single mutations in the codon 531 of the rpoB gene and
codon 315 of the katG gene) was similar or close to previ-
ously reported on larger populations in Samara and other
regions of Russian Federation [20,31-33]. The proportion
of drug resistant strains in which no mutations were
detected was low (3.8% and 2.7% for RIF and INH resist-
ance) suggesting that the set of the DNA probes used in
the GenoType® MTBDRplus assay covers most of the
mutations prevailing in the Russian Federation. Previ-
ously reported associations between the above mutations
and Beijing strains [20,34] suggest that the assay may be
WT S315T1 WT WT C15T, A16G 3 2.6
WT S315T1 WT Δwt - 1 0.9
WT S315T1 Δwt Δwt - 1 0.9
Table 2: Variety of mutations associated with RIF and INH resistance (sputum specimens) (Continued)
Table 3: Performance of GenoType® MTBDRplus assay in 
detection of RIF, INH and MDR resistance in sputum specimens 
(N = 149)
RIF INH MDR Fully sensitive
Sensitivity (%) 96.2 97.4 97.1 88.2
Specificity (%) 90.7 83.3 88.9 97.4
PPV (%) 96.2 94.8 95.3 90.0
NPV (%) 90.7 90.9 93.0 96.6
All rates were calculated vs phenotypic results (BACTEC MGIT)
NPV – Negative predictive value
PPV – Positive predictive valuePage 6 of 9
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prevalence of Beijing family isolates (Eastern Europe,
China and South-East Asia).
The proportion of interpretable GenoType® MTBDRplus
assay results in our study, i.e. sensitivity of the assay for
detection of TB bacilli (91.7%) was high but slightly lower
compared to that reported previously (96.8% and 98.6%
in [19] and [11] respectively), and, contrary to previous
publications, lower readability rates were clearly associ-
ated with lower AFB grading in smear microscopy results.
The performance of the assay on sputum samples with
low concentrations of TB bacilli could probably be
enhanced through the use of alternative methods of spu-
tum treatment, potentially involving concentration of
microorganisms prior to DNA extraction. An increased
number of PCR cycles (40 cycles for sputum analysis com-
pared to 30 cycles for cultures) does not resolve this prob-
lem completely and increases the sensitivity of the assay to
amplicon contamination.
Overall sensitivity of the GenoType® MTBDRplus assay for
detection of RIF, INH and multidrug resistance was high
at 96.2%, 97.4%, and 97.1% respectively, which is similar
to previously reported results in studies from South Africa,
Germany, and Italy [11,18,19] supporting the use of this
assay for MDRTB screening. Specificity and negative pre-
dictive values were 90.7%, 83.3%, and 88.9% for
rifampicin, isolniazid, and MDR respectively suggesting
that the molecular assay slightly overestimates drug resist-
ance as defined by phenotypic DST on cultures derived
from relevant sputum specimens. We believe that these
discrepant results (10 disagreements in total), as well as
"double patterns" in a proportion of strips (25.8%) could
be explained by a "heteroresistance", i.e simultaneous
presence of both drug resistant and sensitive TB bacilli in
clinical samples.
We hypothesized that in these cases initial sputum sam-
ples contained mixtures of resistant and sensitive bacilli
and, whilst mutant genotypes were recognized by the
molecular assay (therefore masking sensitive genotypes)
the sensitive bacilli might have grown preferentially on
liquid media giving "sensitive" phenotypic DST results.
Heteroresistance, initially reported by Rinder et al. [35], is
an important factor which can affect the accuracy and reli-
ability of drug susceptibility testing using clinical speci-
Table 4: Analysis of disagreements between molecular (sputum specimens and cultures) and phenotypical DST results
Molecular DST Phenotypical DST
Sputum Culture
ID GenoType® MTBDRplus pattern
RIF INH rpoB katG inhA RIF INH RIF INH
007–035 S S WT WT WT S S R R
007–060 S R WT Δwt S315T1 WT S S S S
007–069 R R Δ8
S531L
WT WT, C15T S S R S
007–086 R R Δ7,Δ8 WT
S315T1
WT S S S S
007–088 R R Δ8
S531L
Δwt S315T1 WT S S S R
007–100 S S WT WT WT S S S R
007–121 S R WT WT
S315T1
WT R* R** R R
007–127 S R WT WT
S315T1
WT S S S S




Δwt C15T S R** S S
007–149 S R WT Δwt S315T1 WT n/a n/a R S
007–153 R R Δ8
S531L
Δwt S315T1 WT S R*** S R
007–166 S S WT WT WT n/a n/a R R
Notes: ΔN (N = 2...8) – missing WT probe
WT – all WT probes are present
Δwt – missing WT probe(s)
* – GenoType® MTBDRplus pattern Δ8 S531L
** – GenoType® MTBDRplus pattern WT S315T1
*** – GenoType® MTBDRplus pattern Δwt S315T1Page 7 of 9
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cultures may not be representative of the initial mixture of
Mycobacteria in the sputum. This usually underestimated
phenomenon complicates interpretation of diagnostic
assay results and may have been a reason for discordant
results and "double patterns" (positive hybridization with
mutant and wild type probes) on GenoType® MTBDR and
GenoType® MTBDRplus membranes in our and recent
studies [15,18]. We assume that heteroresistance is more
likely to occur in high TB incidence areas and in cultures
isolated from chronic patients as they have more opportu-
nity to become infected with various populations of Myco-
bacteria [36]; therefore "double patterns" were more
common in our collection of samples obtained in high TB
drug resistance region. Heteroresistance should be further
investigated by molecular fingerprinting of clinical speci-
mens (eg PCR-based VNTR typing) and detection of muta-
tions in artificial "spiked" sputum specimens to establish
mechanisms of preferential recognition of certain geno-
types present in the specimen.
Conclusion
The GenoType® MTBDRplus assay is a sensitive and spe-
cific tool for diagnosis of RIF, INH resistance and MDR in
sputum specimens. The short turnaround times and the
potential for rapid screening of large numbers of speci-
mens make it suitable as a first-line screening assay for TB
drug resistance
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